Home » Topics » BioWorld Science

BioWorld Science
RSS

Grant supports Cognition's evaluation of sigma-2 receptor modulators for Parkinson's disease

Jan. 5, 2022

Novel covalent BTK inhibitor with good potency and reduced CYP inhibitory activity

Jan. 5, 2022

Dusquetide effective at reducing tumor size in nonclinical xenograft models

Jan. 5, 2022

Biogen exercises option to license preclinical ASO for spinal muscular atrophy

Jan. 5, 2022

Discovery of novel selective and orally bioavailable AR-V7 degrader

Jan. 5, 2022

Merck & Co. synthesizes RIPK1 inhibitors

Jan. 5, 2022

Vertex Pharmaceuticals identifies new APOL1 inhibitors

Jan. 5, 2022

Novartis presents new Cav1.2 activators

Jan. 5, 2022

Incyte divulges new ACVR1 inhibitors

Jan. 5, 2022

MCUF-651, a GC-A PAM for the treatment of cardiovascular, renal and metabolic diseases

Jan. 5, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...